409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
About this episode
The episode discusses prediction markets in biotech and a controversial Alzheimer's drug from Biogen.
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. Soon, you’ll be able to make bets on the outcomes of clinical trials and FDA drug reviews. Is that a good thing? We’ll discuss the issues with Jonathan Kimmelman, a bioethicist at McGill University who has researched prediction in clinical trials. We also chat about Biogen and its tau-lowering drug for Alzheimer’s. A mid-stage clinical trial presented this week showed the drug reduced levels of the tau protein and slowed the rate of cognitive decline in patients. But the data also raised a lot of questions that left experts and investors debating the drug’s future.
More episodes of The Readout Loud
- 408: Whistleblower takes on health insurance and FDA commissioner candidates
- 407: The mysterious case of Eli Lilly's obesity drug
- 406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.